Biotech stocks are not doing well in this risk-off market. I would not recommend trying to swing trade biotechnology stocks because so much money is being pulled out of them
With the big ASH meeting ongoing, we have more biotech stocks to watch for big news in the week ahead. I'm feeling better about risk-on biotech stocks with the Federal
Biotech stock Immune Design (IMDZ) just released the big news we have been waiting for over this weekend's news cycle. Immune Design just announced long-term follow up results from a
Biotech stocks have really sold-off in this risk-off market. With the Russell 2000 extremely weak right now it's still too early to go long most penny stocks. However, biotech stocks
Small cap penny stocks can make huge moves but in this risk-off market, they are VERY risky. The best penny stocks will go down in a risk-off market unless the
The annual ASH meeting begins on December 1, 2018. The annual ASH meeting is regarded by many as THE major biotechnology conference of the year. Lots of companies will be
Ablynx stock is a late-stage clinical development company that is finally going to bring a product to market in Germany in 2018.
Ampliphi Biosciences stock has rising large players volume after the company released incredible phase 1 trial results from their phage therapy cure for antibiotic resistant superbugs.
Galapagos stock could be an attractive acquisition for Gilead, so as the rumors go.
Galectin Therapeutics stock is a completely technical play on an oversold chart setup. This is a quick swing move up gambit as the company reports Phase 2b top-line data.